Body Dysmorphic Disorder Clinical Trial
Official title:
Online Cognitive Behavioural Therapy (CBT) Intervention for Body Dysmorphic Disorder: Comparison of CBT - Mindfulness to CBT Alone
Verified date | July 2023 |
Source | York University |
Contact | Paul Ritvo, PhD |
Phone | 4165808021 |
pritvo[@]yorku.ca | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Body Dysmorphic Disorder (BDD) affects 2.3% of the population and is characterized by excessive concerns with imagined or minor defects in physical appearance. Retrospective outcome studies suggest patients affected by BDD don't typically benefit from surgical treatments while cognitive behaviour therapy (CBT) appears to provide symptom - reducing and distress - reducing benefits. Two different 8-week online CBT approaches to assisting individuals with this disorder are compared: one approach will integrate mindfulness meditation methods (in combination with CBT) and one approach will employ CBT methods without reference to mindfulness meditation.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | November 1, 2023 |
Est. primary completion date | October 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: On the Body Dysmorphic Disorder Questionnaire, responses indicating current BDD status; - Exclusion Criteria: Individuals who are currently receiving weekly structured psychotherapy or who meet DSM-V criteria for severe alcohol/substance use disorder in the past 3 months or demonstrated clinically significant suicidal ideation defined as imminent intent, or attempted suicide in the past 6 months. Individuals of co-morbid diagnoses of borderline personality, schizophrenia, bipolar disorder and/or obsessive compulsive disorder are excluded. - |
Country | Name | City | State |
---|---|---|---|
Canada | York University | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
York University |
Canada,
Kuck N, Cafitz L, Burkner PC, Hoppen L, Wilhelm S, Buhlmann U. Body dysmorphic disorder and self-esteem: a meta-analysis. BMC Psychiatry. 2021 Jun 15;21(1):310. doi: 10.1186/s12888-021-03185-3. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | General Anxiety Disorder - 7 | A 7-item self report scale that asks for symptoms of anxiety | Baseline, Post-Intervention at 8 weeks following Baseline | |
Other | Brief Pain Inventory | A 11-item self report scale that asks for symptoms of pain experience | Baseline, Post-Intervention at 8 weeks following Baseline | |
Primary | Body Dysmorphic Disorder Symptom Scale | A 55-item scale which asks for presence/absence of symptoms and the degree of severity | Baseline, Post-Intervention at 8 weeks following Baseline | |
Secondary | Patient Health Questionnaire - 9 | A 9-item self report scale that asks for symptoms of depression and anxiety | Baseline, Post-Intervention at 8 weeks following Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02635152 -
Interpretation Bias Modification for Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT03673046 -
Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)
|
N/A | |
Withdrawn |
NCT02843451 -
Milk Thistle in Body Dysmorphic Disorder
|
Phase 2 | |
Completed |
NCT02010619 -
Internet Delivered CBT for Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT00842309 -
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
|
Early Phase 1 | |
Completed |
NCT00245635 -
Fluoxetine in Pediatric Body Dysmorphic Disorder
|
Phase 4 | |
Completed |
NCT02808702 -
Brain Correlates of Self-Focused Processing
|
N/A | |
Completed |
NCT01002326 -
Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder
|
N/A | |
Active, not recruiting |
NCT01075672 -
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
|
N/A | |
Completed |
NCT02671266 -
Oxytocin Administration in BDD and OCD
|
Phase 2 | |
Completed |
NCT01038128 -
An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT01398865 -
Escitalopram Neuroimaging Supplement
|
N/A | |
Completed |
NCT00265109 -
Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder
|
Phase 4 | |
Recruiting |
NCT04373629 -
Perceptual Abnormalities and Their Malleability in BDD
|
N/A | |
Completed |
NCT01453439 -
Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT00871143 -
Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD)
|
N/A | |
Completed |
NCT00106223 -
Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder
|
N/A | |
Active, not recruiting |
NCT00211809 -
CBT as an Adjunct to SRIs in the Treatment of BDD
|
Phase 4 |